Olaparib + Zytiga for Metastatic Castrate-Resistant Prostate Cancer: PCRI video

[Admin]

Jim Marshall (not a doctor) said ...

In this video Prostate Cancer Research Institute Executive Director Mark Scholz talks about a clinical trial for men who are metastatic and have rising psa on hormone therapy.

The trial is testing whether adding the PARP inhibitor Lynparza (olaparib) to the super-hormone Zytiga (abiraterone) increases its effectiveness.

 

You can find out about the clinical trial at:

https://clinicaltrials.gov/ct2/show/study/NCT03732820?show_locs=Y#locn

Details there include:

• inclusion details (things you need to get into the trial);
• exclusion details (what will keep you out of the trial); and
• locations.

Australian locations include:

• Box Hill, Australia, 3128
• Darlinghurst, Australia, 2010
• Greenslopes, Australia, 4120
• Herston, Australia, 4029
• Kingswood, Australia, 2747
• Kurralta Park, Australia, 5037
• St Albans, Australia, 3021
• Waratah, Australia, 2298

 

As always, ask your doctor if you think this might be for you.

... end Jim

 

 

 

[ardee]

What's the theory behind adding a PAR-I if a man is NOT BRCA+??? To me it sounds like throwing spaghetti at the wall to see what sticks.  Scholz throws very little if any light on why they are combining these two drugs.